Milestone Pharmaceuticals (NASDAQ:MIST) Releases Earnings Results

Milestone Pharmaceuticals (NASDAQ:MIST) issued its quarterly earnings data on Tuesday. The company reported ($1.04) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.48) by ($0.56), Fidelity Earnings reports.

NASDAQ:MIST traded up $1.24 during trading hours on Wednesday, hitting $18.04. 110 shares of the stock traded hands, compared to its average volume of 35,768. The business’s 50 day simple moving average is $19.55. Milestone Pharmaceuticals has a fifty-two week low of $15.09 and a fifty-two week high of $27.95.

MIST has been the topic of a number of recent analyst reports. Oppenheimer initiated coverage on shares of Milestone Pharmaceuticals in a research report on Tuesday, June 4th. They set an “outperform” rating and a $32.00 price target on the stock. Jefferies Financial Group began coverage on Milestone Pharmaceuticals in a report on Monday, June 3rd. They issued a “buy” rating and a $28.00 price target for the company. CIBC began coverage on Milestone Pharmaceuticals in a report on Tuesday, June 4th. They issued an “outperform” rating and a $32.00 price target for the company. Piper Jaffray Companies began coverage on Milestone Pharmaceuticals in a report on Monday, June 3rd. They issued an “overweight” rating and a $26.50 price target for the company. Finally, Cowen began coverage on Milestone Pharmaceuticals in a report on Monday, June 3rd. They issued an “outperform” rating and a $32.00 price target for the company. Five investment analysts have rated the stock with a buy rating, The company presently has an average rating of “Buy” and an average target price of $30.10.



Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals Inc, a biopharmaceutical company, develops and commercializes drugs for the treatment of cardiovascular indications. It offers Etripamil that completed Phase 2 clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada, as well as for treating Atrial Fibrillation and Angina.

Featured Story: What is a short straddle?

Receive News & Ratings for Milestone Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Milestone Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.